Document is current
Any future updates will be listed below
-
Authors
Haack, Daniel B. https://orcid.org/0000-0002-4926-7772
Rudolfs, Boris
Jin, Shouhong
Khitun, Alexandra
Weeks, Kevin M. https://orcid.org/0000-0002-6748-9985
Toor, Navtej https://orcid.org/0000-0002-6134-163X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM141706)
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 18 December 2024
First Online: 21 January 2025
Competing interests
: A provisional patent application has been filed on the use of the group II intron as the scaffolding technology described here with D.B.H., B.R., and N.T. listed as co-inventors. D.B.H., K.M.W., and N.T. are co-founders of A-Form Solutions; N.T. is a co-founder of Syrna Therapeutics; K.M.W. is an advisor to and holds equity in ForagR Medicines and Ribometrix. All other authors declare they have no competing interests.
